GABAA Receptor ß1 Antibody

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system, causing a hyperpolarization of the membrane through the opening of a Cl− channel associated with the GABA-A receptor (GABA-A-R) subtype. GABA-A-Rs are important therapeutic targets for a range of sedative, anxiolytic, and hypnotic agents and are implicated in several diseases including epilepsy, anxiety, depression, and substance abuse. The GABA-A-R is a multimeric subunit complex. To date six αs, four βs and four γs, plus alternative splicing variants of some of these subunits, have been identified (Olsen and Tobin, 1990; Whiting et al., 1999; Ogris et al., 2004) . Injection in oocytes or mammalian cell lines of cRNA coding for α- and β-subunits results in the expression of functional GABA-A-Rs sensitive to GABA. However, coexpression of a γ-subunit is required for benzodiazepine modulation. The various effects of the benzodiazepines in brain may also be mediated via different α-subunits of the receptor (McKernan et al., 2000; Mehta and Ticku, 1998; Ogris et al., 2004; Pöltl et al., 2003) .

AW061132 antibody, B230208N19Rik antibody, GABA (A) receptor beta 1 antibody, GABA (A) receptor subunit beta-1 antibody, GABA-A receptor beta-1 polypeptide antibody, Gabrb-1 antibody, GABRB1 antibody, Gamma aminobutyric acid (GABA) A receptor beta 1 antibody, Gamma Aminobutyric Acid A Receptor Beta 1 antibody, Gamma Aminobutyric Acid Receptor beta-1 antibody, Gamma-aminobutyric acid (GABA) A receptor subunit beta 1 antibody, Gamma-aminobutyric acid receptor subunit beta-1 antibody, GARB1 antibody, GBRB1_HUMAN antibody